0001181431-13-054616.txt : 20131021 0001181431-13-054616.hdr.sgml : 20131021 20131021163114 ACCESSION NUMBER: 0001181431-13-054616 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20131018 FILED AS OF DATE: 20131021 DATE AS OF CHANGE: 20131021 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: PUMA BIOTECHNOLOGY, INC. CENTRAL INDEX KEY: 0001401667 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 770683487 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 10880 WILSHIRE BLVD. STREET 2: SUITE 2150 CITY: LOS ANGELES STATE: CA ZIP: 90024 BUSINESS PHONE: (424) 248-6500 MAIL ADDRESS: STREET 1: 10880 WILSHIRE BLVD. STREET 2: SUITE 2150 CITY: LOS ANGELES STATE: CA ZIP: 90024 FORMER COMPANY: FORMER CONFORMED NAME: INNOVATIVE ACQUISITIONS CORP DATE OF NAME CHANGE: 20070601 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: WILSON TROY EDWARD CENTRAL INDEX KEY: 0001589597 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-35703 FILM NUMBER: 131161684 MAIL ADDRESS: STREET 1: C/O PUMA BIOTECHNOLOGY INC. STREET 2: 10880 WILSHIRE BOULEVARD, SUITE 2150 CITY: LOS ANGELES STATE: CA ZIP: 90024 4 1 rrd393046.xml WILSON F4 X0306 4 2013-10-18 0 0001401667 PUMA BIOTECHNOLOGY, INC. PBYI 0001589597 WILSON TROY EDWARD C/O PUMA BIOTECHNOLOGY, INC. 10880 WILSHIRE BLVD., SUITE 2150 LOS ANGELES CA 90024 1 0 0 0 STOCK OPTION (RIGHT TO BUY) 44.96 2013-10-18 4 A 0 40000 0 A 2023-10-18 COMMON STOCK 40000 40000 D The vesting commencement date ("Vesting Commencement Date") of the option is October 18, 2013. The option vests (i) with respect to one-third (1/3) of the shares underlying the option on the first anniversary of the Vesting Commencement Date and (ii) with respect to one-thirty sixth (1/36th) of the shares underlying the option, on each monthly anniversary of the Vesting Commencement Date thereafter, subject to (a) the Reporting Person's continued service on the Audit Committee, with respect to 10,000 of the 40,000 underlying shares, and (b) the Reporting Person's continued service with the Issuer, with respect to the remaining 30,000 of the 40,000 underlying shares. /s/ Troy Edward Wilson 2013-10-21